Company intelligence / Profile preview

Microbix Biosystems

Mississauga, Ontario, Canadamicrobix.com ↗

Ownership: Public · MBX
Employees: ~70
Development stage: Commercial

Overview

Microbix commercializes a broad portfolio of diagnostic antigens and quality assessment products used globally in clinical labs. Its QAPs™ line supports proficiency testing and assay validation across a wide range of infectious disease diagnostics. The company also owns Kinlytic® urokinase, a biologic thrombolytic drug previously approved in the US but currently seeking new commercialization partners[1][3][4].

Therapeutic areas: CardiovascularInfectious Diseases
Modalities: AntigenBiologicRecombinant protein
Industry: Biotech

Drug pipeline

1 asset

urokinase

Approved

Partnerships

Partners sought for Kinlytic® urokinase outlicensingmajor sales to clinical laboratory accreditation agencies

Beyond the preview

Go deeper on Microbix Biosystems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microbix Biosystems.

Explore the full profile